Lilly's Cymbalta gets closer to FDA approval

One year after receiving its first conditional approval for its experimental depression medicine, Cymbalta, Eli Lilly said it received a second notice from the FDA on Wednesday saying the company does not need to conduct more clinical trials to get approval. However, Lilly still must resolve issues with its plant where Cymbalta is made.

View Full Article in:

MSNBC · Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR